Dr Noa Krugliak Cleveland M.D., CCC 2022: Vedolizumab in Ulcerative Colitis – Data from RALEE
We were delighted to speak with Dr Noa Krugliak Cleveland M.D. (University of Chicago, Chicago, IL, USA) around her talk on the RALEE study, investigating the impact of early initiation of vedolizumab in UC.
The abstract ‘EARLY VERSUS DELAYED INITIATION OF VEDOLIZUMAB IN ULCERATIVE COLITIS: TREATMENT RESPONSE IN THE REAL WORLD (RALEE)’ which was presented at the virtual 2022 Crohn’s & Colitis Congress, 20-22 January, 2022.
- What is known about the effect of timing of initiation of biologic therapies in ulcerative colitis? (0:10)
- What were the aims and design of the RALEE study? (0:58)
- What did the study tell us about patient characteristics and treatment patterns? (1:28)
- What can be done to ensure treatment patterns more closely match the guidelines? (2:13)
Disclosures: Noa Krugliak Cleveland discloses consulting for Takeda.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the virtual Crohn’s & Colitis Congress 2022.
Share this Video
Related Videos In Digestive Disorders
UEG Digestive Health Month: Matthias Löhr, May 2023
Digestive Health Month took place over May 2023 to raise awareness of digestive diseases and cancers, which often remain overlooked in terms of policy, funding and research in Europe. We were delighted to talk with UEG’s Vice President Prof. Matthias Löhr (Karolinska Institutet, Stockholm, Sweden) around the public health and economic burden of digestive diseases, […]
Stefan Schreiber, ECCO’23: Corticosteroid-free remission with etrasimod in ulcerative colitis – analysis of the ELEVATE UC 52 study
The ELEVATE UC 52 study (NCT03945188) investigated the efficacy and safety of etrasimod in patients with moderately to severely active ulcerative colitis, a recent analysis of the study was presented at ECCO’23 looking at corticosteroid (CS)-free remission as a clinical endpoint. In this touchIMMUNOLOGY interview, we spoke with Dr. Stefan Schreiber (University Hospital Schleswig-Holstein, Kiel, […]
Stefan Schreiber, ECCO’23: Current treatment paradigm for ulcerative colitis and corticosteroid-free remission as a treatment goal
The current treatment paradigm for ulcerative colitis (UC) includes amino salicylic acid as a first line treatment followed by corticosteroids, targeted treatment and rectal topical therapy; however, with corticosteroids (CS) impacting long-term health, CS-free remission has become a long-term goal in treatment. Etrasimod is an S1P receptor modulator, recently investigated for the treatment of UC […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!